Filing Details

Accession Number:
0001140361-22-045111
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-12-09 16:41:13
Reporting Period:
2022-12-09
Accepted Time:
2022-12-09 16:41:13
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1368514 Adma Biologics Inc. ADMA Biological Products, (No Disgnostic Substances) (2836) 562590442
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1542517 S Adam Grossman C/O Adma Biologics, Inc.
465 State Route 17
Ramsey NJ 07446
President And Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-12-09 14,983 $2.86 2,203,708 No 4 P Direct
Common Stock Acquisiton 2022-12-09 14,982 $2.86 1,143,426 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 580,957 Indirect See Footnote
Footnotes
  1. Represents a purchase from the underwriters in the December 2022 public offering of the issuer.
  2. Includes (i) 300,000 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 907,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (continued)
  3. (continued from prior footnote) (iii) 162,893 unvested RSUs granted on February 25, 2021, of which 137,362 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 25,531 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (continued)
  4. (continued from prior footnote) (iv) 50,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 783,315 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  5. These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
  6. These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.